A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Exclusion Criteria

• •History of primary progressive multiple sclerosis (PPMS), progressive relapsing multiple sclerosis (PRMS), or secondary progressive multiple sclerosis (SPMS)
• •Contraindications for MRI
• •Known presence of other neurological disorders that may mimic multiple sclerosis
• •Pregnancy or lactation, or intention to become pregnant during the study
• •Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
• •History of or currently active primary or secondary immunodeficiency
• •Lack of peripheral venous access
• •History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
• •Active infection, or history of or known presence of recurrent or chronic infection such as human immunodeficiency virus (HIV), syphilis, or tuberculosis
• •History of progressive multifocal leukoencephalopathy
• •Contraindications to or intolerance of oral or IV corticosteroids
• •Previous treatment with fingolimod (Gilenya®) or dimethyl fumarate (Tecfidera®) in participants whose lymphocyte count is below the lower limit of normal (LLN)
• •Treatment with alemtuzumab (Lemtrada®)
• •Previous treatment with systemic cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, or methotrexate
• •Previous treatment with natalizumab within 12 months prior to screening unless failure was due to confirmed, persistent anti-drug antibodies (ADAs). Participants previously treated with natalizumab will be eligible for this study only if duration of treatment with natalizumab was less than (\<) 1 year and natalizumab was not used in the 12 months prior to screening. Anti-John Cunningham virus (JCV) antibody status (positive or negative) and titer (both assessed within the year of screening) must be documented prior to enrollment
• •Treatment with dalfampridine (Ampyra®) unless on stable dose for \>/=30 days prior to screening
• •Treatment with a B-cell targeted therapies (e.g., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
• •Treatment with a drug that is experimental (Exception: treatment with an experimental drug that was subsequently approved in the participant's country is allowed)